Flavimonas oryzihabitans bacteremia: clinical features and microbiological characteristics of isolates.
Flavimonas oryzihabitans is rarely reported as a pathogen in humans. Twelve cases of F. oryzihabitans bacteremia were diagnosed at National Taiwan University Hospital over a 3-year period. The clinical features of these patients were analyzed, and antimicrobial susceptibilities and random amplified polymorphic DNA (RAPD) patterns of the 12 isolates were studied. Among these 12 patients, eight (67%) had underlying neoplastic diseases and all acquired F. oryzihabitans bacteremia while hospitalized. The clinical syndromes included primary bacteremia in 5 patients (42%), biliary tract infection in 3 (25%), and peritonitis, subdural empyema, infusion-related bacteremia, and pneumonia in 1 each. Polymicrobial bacteremia or concomitant fungemia was seen in three patients (25%). All the patients survived after antibiotic treatment. All isolates were susceptible to piperacillin, third-generation cephalosporins, aminoglycosides, and quinolones but resistant to cephalothin, cefuroxime, and trimethoprim. Susceptibility to aztreonam was variable (25%). The RAPD patterns differed among the isolates, indicating the epidemiological unrelatedness of these infections. F. oryzihabitans should be included as an etiology of severe nosocomial infection in patients with underlying debilitating diseases.
Lin
R D
RD
Department of Laboratory Medicine, National Taiwan University Hospital, and the School of Medical Technology, National Taiwan University, Taipei.
Hsueh
P R
PR
Chang
J C
JC
Teng
L J
LJ
Chang
S C
SC
Ho
S W
SW
Hsieh
W C
WC
Luh
K T
KT
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D002675:Child, Preschool; D004269:DNA, Bacterial / Q000032:analysis*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011549:Pseudomonas / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D015996:Survival Rate; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial